NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11th April 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Alistair Patton Present for all items
4. Dr Andrew Makin Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Francis Drobniewski Items 1.1 to 5.3.1
7. Dr Hatim Abdulhussein Items 1.1 to 4.3.2
8. Dr Mark Tanner Items 1.1 to 4.3.2
9. Dr Natalia Kunst Present for all items
10. Dr Rhiannon Owen Present for all items
11. Dr Warren Linley Present for all items
12. Gabriel Rogers  Present for all items
13. Lisa Attrill Present for all items
14. Nigel Westwood Present for all items
15. Peter Wheatley-Price Present for all items
16. Tony Wootton Present for all items
17. Vanessa Danielson Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.3.2

Carl Jackson, Assistant Project Manager Items 1.1 to 4.3.2

Victoria Kelly, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Raphael Egbu, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Ishbel McCallum, Administrator Items 1.1 to 4.3.2

Ian Watson, Associate Director Items 5.1 to 5.3.2

Jeremy Powell, Project Manager Items 5.1 to 5.3.2

Adam Brooke, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Samuel Slayen, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Louise Jones, Administrator, Technology Appraisals Items 5.1 to 5.3.2

External assessment group representatives present

Karen Pickett, Southampton Health Technology Assessments Centre (SHTAC)

 Items 1.1 to 4.2.1

Jo Lord, Southampton Health Technology Assessments Centre (SHTAC)

 Items 1.1 to 4.2.1

Ash Bullement, Peninsula Technology Assessment Group Items 5.1 to 5.2.1

Darren Burns, Peninsula Technology Assessment Group Items 5.1 to 5.2.1

Clinical, Patient & NHS England experts present

Anthony Bewley, Consultant Dermatologist and Honorary Professor of Dermatology -Clinical expert, nominated by British Association of Dermatologists (BAD)

 Items 1.1 to 4.2.1

Richard Weller, Personal Chair of Medical Dermatology / Honorary Consultant Dermatologist, Clinical expert, nominated by Almirall Items 1.1 to 4.2.1

Andrew Proctor, Chief executive - Patient expert, nominated by The National Eczema Society Items 1.1 to 4.2.1

Stephen Pugh, Chair and Trustee - Patient expert, nominated by The National Eczema Society Items 1.1 to 4.2.1

Fiona Marley, NHS Commissioning Expert Nominated by NHS England

 Items 5.1 to 5.2.1

Dr Sam Amin, Consultant Paediatric Neurologist, Clinical Expert nominated by BPNA

 Items 5.1 to 5.2.1

Carol-Anne Partridge, Patient Expert, Chairperson and Co-founder, Nominated by CDKL5 UK Items 5.1 to 5.2.1

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Baljit Singh, welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Toby Smith, Bushra Hasnie, David McAllister, Anna Pracz,, Stuart Williams and Veline L’Esperance.

### News and announcements

* 1. List any other business or record ‘none’.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 14th March.
1. **Appraisal of** [**Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta11349)
	1. Part 1 – Open session
		1. The chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Almirall.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11349).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Nigel Westwood (lay), Andrew Makin (clinical) and Warren Linley (cost).
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, patient and clinical experts, external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11349>.
1. **Appraisal of** [**Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948)
	1. Part 1 – Open session
		1. The chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Orion Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh and Adam Brooke.
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10948>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 15th May and will start promptly at 9am.